Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) traded up 7% on Monday . The stock traded as high as $11.84 and last traded at $11.84. 8,515 shares were traded during mid-day trading, a decline of 96% from the average session volume of 213,318 shares. The stock had previously closed at $11.07.
Analyst Ratings Changes
A number of brokerages have weighed in on SION. TD Cowen assumed coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating on the stock. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a report on Tuesday, March 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Finally, Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a "buy" rating and a $45.00 price target for the company.
View Our Latest Analysis on Sionna Therapeutics
Sionna Therapeutics Stock Down 3.7 %
The stock has a fifty day moving average price of $12.99.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.68) by ($0.70).
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
